Overview

Study on the Efficacy of Radiotherapy Added to Pembrolizumab in Newly Diagnosed Metastatic Head and Neck Cancers

Status:
Recruiting
Trial end date:
2029-09-15
Target enrollment:
Participant gender:
Summary
Trial evaluating the efficacy of radiotherapy added to pembrolizumab compared to pembrolizumab alone for patients with newly diagnosed head and neck carcinoma with metastases
Phase:
Phase 3
Details
Lead Sponsor:
UNICANCER
Collaborators:
GORTEC
National Cancer Institute, France
Treatments:
Pembrolizumab